The estimated Net Worth of Michel Vounatsos is at least $32.1 Миллион dollars as of 18 February 2022. Mr. Vounatsos owns over 6,191 units of Biogen Inc stock worth over $13,937,694 and over the last 8 years he sold BIIB stock worth over $0. In addition, he makes $18,159,900 as Chief Executive Officer и Director at Biogen Inc.
Michel has made over 16 trades of the Biogen Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently he exercised 6,191 units of BIIB stock worth $1,232,566 on 18 February 2022.
The largest trade he's ever made was exercising 16,289 units of Biogen Inc stock on 12 February 2021 worth over $3,242,977. On average, Michel trades about 2,714 units every 61 days since 2016. As of 18 February 2022 he still owns at least 70,007 units of Biogen Inc stock.
You can see the complete history of Mr. Vounatsos stock trades at the bottom of the page.
Michel Vounatsos has served as the Chief Executive Officer and Director of Biogen Inc. Prior to that, from April 2016 to December 2016, Mr. Vounatsos served as our Executive Vice President and Chief Commercial Officer. Prior to that, from April 2016 until his appointment as our Chief Executive Officer, he served as our Executive Vice President, Chief Commercial Officer. Prior to joining Biogen, Mr. Vounatsos spent 20 years at Merck & Co., Inc., a pharmaceutical company, where he most recently served as President, Primary Care, Customer Business Line and Merck Customer Centricity. In this role, he led Merck’s global primary care business unit, a role which encompassed Merck’s cardiology-metabolic, general medicine, women’s health and biosimilars groups and developed and instituted a strategic framework for enhancing the company’s relationships with key constituents, including the most significant providers, payers and retailers and the world’s largest governments. Mr. Vounatsos previously held leadership positions across Europe and in China for Merck. Prior to that, Mr. Vounatsos held management positions at Ciba-Geigy, a pharmaceutical company. Mr. Vounatsos currently serves on the advisory board of Tsinghua University School of Pharmaceutical Sciences and as a member of the MIT Presidential CEO Advisory Board. Mr. Vounatsos received his C.S.C.T. certificate in Medicine from the Universite Victor Segalen, Bordeaux II, France, and his M.B.A. from the HEC School of Management in Paris.
As the Chief Executive Officer и Director of Biogen Inc, the total compensation of Michel Vounatsos at Biogen Inc is $18,159,900. There are no executives at Biogen Inc getting paid more.
Michel Vounatsos is 58, he's been the Chief Executive Officer и Director of Biogen Inc since 2017. There are 12 older and 11 younger executives at Biogen Inc. The oldest executive at Biogen Inc is Stelios Papadopoulos, 72, who is the Independent Chairman of the Board.
Michel's mailing address filed with the SEC is C/O ZAI LAB LIMITED, 314 MAIN STREET, 4TH FLOOR, SUITE 100, CAMBRIDGE, MA, 02142.
Over the last 21 years, insiders at Biogen Inc have traded over $166,883,156 worth of Biogen Inc stock and bought 665,319 units worth $183,001,783 . The most active insiders traders include Adam Koppel, Alexander J Denner и Stelios Papadopoulos. On average, Biogen Inc executives and independent directors trade stock every 10 days with the average trade being worth of $2,343,090. The most recent stock trade was executed by Priya Singhal on 30 August 2024, trading 1,668 units of BIIB stock currently worth $332,082.
through cutting-edge science and medicine, biogen discovers, develops and delivers innovative therapies worldwide for people living with serious neurological and neurodegenerative diseases. founded in 1978, biogen is a pioneer in biotechnology and today the company has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first and only approved treatment for spinal muscular atrophy, and is at the forefront of neurology research for conditions including alzheimer’s disease, parkinson’s disease and amyotrophic lateral sclerosis. biogen also manufactures and commercializes biosimilars of advanced biologics. with approximately 7000 people worldwide, we are truly a global organization, headquartered in cambridge, massachusetts, which is also home to our research operations. our international headquarters are based in zug, switzerland and we have world-class manufacturing facilities in north carolina and denmark. we offer therapies globally through direct affili
Biogen Inc executives and other stock owners filed with the SEC include: